

MediScore - Oncology

Drug / Indication		Date																
Study						Max. Score												
Data Quality	Evidence Level	I RCT or Metaanalysis with RCT	3															
		II Controlled Study without Randomization or Crossover	2															
		III Study without Control Group or Case Reports	1			3												
	Publication Journal Quality	High Moderate Low	2 1 0			2												
p-Value	OS or PFS ≤ 0,05	1			1													
Efficacy	Δ OS	Under Standard Therapy or Spontaneous Course		HR, if mOS in Study not achieved (OS >50%)														
		<table border="1"> <thead> <tr> <th>if mOS ≤ 1 y</th> <th>1 - 3 y</th> <th>> 3 y</th> </tr> </thead> <tbody> <tr> <td>Δ OS ≥ 3 mths</td> <td>Δ OS ≥ 4 mths</td> <td>Δ OS ≥ 6 mths</td> </tr> <tr> <td>Δ OS ≥ 5 mths</td> <td>Δ OS ≥ 6 mths</td> <td>Δ OS ≥ 9 mths</td> </tr> <tr> <td>Δ OS ≥ 7 mths</td> <td>Δ OS ≥ 8 mths</td> <td>Δ OS ≥ 12 mths</td> </tr> </tbody> </table>	if mOS ≤ 1 y	1 - 3 y	> 3 y	Δ OS ≥ 3 mths	Δ OS ≥ 4 mths	Δ OS ≥ 6 mths	Δ OS ≥ 5 mths	Δ OS ≥ 6 mths	Δ OS ≥ 9 mths	Δ OS ≥ 7 mths	Δ OS ≥ 8 mths	Δ OS ≥ 12 mths		HR > 0.85	0	
		if mOS ≤ 1 y	1 - 3 y	> 3 y														
		Δ OS ≥ 3 mths	Δ OS ≥ 4 mths	Δ OS ≥ 6 mths														
Δ OS ≥ 5 mths	Δ OS ≥ 6 mths	Δ OS ≥ 9 mths																
Δ OS ≥ 7 mths	Δ OS ≥ 8 mths	Δ OS ≥ 12 mths																
	3	HR 0.84 - 0.71	2															
	5	HR 0.70 - 0.55	5															
	8	HR ≤ 0,54	8	8														
Efficacy	Δ PFS measured by RECIST 1.1 or irRC	<table border="1"> <thead> <tr> <th>if mOS ≤ 1 y</th> <th>1 - 3 y</th> <th>> 3 y</th> </tr> </thead> <tbody> <tr> <td>Δ PFS ≥ 2 mths</td> <td>Δ PFS ≥ 3 mths</td> <td>Δ PFS ≥ 5 mths</td> </tr> <tr> <td>Δ PFS ≥ 4 mths</td> <td>Δ PFS ≥ 5 mths</td> <td>Δ PFS ≥ 7 mths</td> </tr> <tr> <td>Δ PFS ≥ 6 mths</td> <td>Δ PFS ≥ 7 mths</td> <td>Δ PFS ≥ 9 mths</td> </tr> </tbody> </table>		if mOS ≤ 1 y	1 - 3 y	> 3 y	Δ PFS ≥ 2 mths	Δ PFS ≥ 3 mths	Δ PFS ≥ 5 mths	Δ PFS ≥ 4 mths	Δ PFS ≥ 5 mths	Δ PFS ≥ 7 mths	Δ PFS ≥ 6 mths	Δ PFS ≥ 7 mths	Δ PFS ≥ 9 mths	HR as Alternative		
		if mOS ≤ 1 y	1 - 3 y	> 3 y														
		Δ PFS ≥ 2 mths	Δ PFS ≥ 3 mths	Δ PFS ≥ 5 mths														
		Δ PFS ≥ 4 mths	Δ PFS ≥ 5 mths	Δ PFS ≥ 7 mths														
Δ PFS ≥ 6 mths	Δ PFS ≥ 7 mths	Δ PFS ≥ 9 mths																
	2	HR > 0.85	0															
	4	HR 0.84 - 0.71	2															
	6	HR 0.70 - 0.55	4															
	6	HR ≤ 0.54	6	6														
Quality of Life	Response Rate measured by RECIST1.1 or irRC	0 - 10 %	0															
		11 - 50 %	1															
		> 50 %	2		2													
	Bonus, if OS < 50% and Plateau-Curve ≥ 30% und ≥ 12 mths ≥ 10% und ≥ 12 mths	+ 4 + 2			Bonus (+4)													
Quality of Life	Adverse Events (AE)	Grade 5	0	QOL as Alternative Significant Improvement Little Effort	5													
		Grade 3 / 4	1	Substantial Effort	4													
		> 50 % > 30 % > 10 % ≤ 10 %	2 3 4	Moderate Improvement Little Effort Substantial Effort	3 2													
		Grade 1-2	5	Minimal Improvement Little Effort Substantial Effort	1 0													
Score Points		Category <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D																
						27												